Showing 2644 results
- Media Release /Sandoz receives positive CHMP opinions for biosimilars rituximab and etanercept to treat immunological diseases. Biosimilar rituximab also recommended to treat blood cancers Comprehensive…
- Media Release /NIH study found 58% of patients with treatment-naïve severe aplastic anemia (SAA) achieved a complete response when eltrombopag was given at the initiation of and concurrently with standard…
- Media Release /Phase IIb clinical trial to evaluate a combination of a Novartis FXR agonist and Allergan's cenicriviroc for NASH, a progressive form of non-alcoholic fatty liver disease There are…
- Key Release /Ad hoc announcement pursuant to Art. 53 LR Novartis executes separation of the Sandoz business to create an independent company by way of a 100% Spin-offShares of Sandoz will be listed and…
- Media Release /Designation prioritizes investigational CTL019 (tisagenlecleucel) as a potential treatment for adult patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL) R/r DLBCL…
- Media Release /Sandoz is seeking approval for all indications included in the reference product's label which includes chronic inflammatory conditions like rheumatoid arthritis and psoriasis. Sandoz believes…
- Media Release /55 of 59 patients experienced complete remissions in a single-arm study of the largest investigational CART therapy in children and young adults[1] Additional data presented include analyses on…
- Media Release /PROTECT 2 study compared safety and efficacy of the proposed biosimilar pegfilgrastim with the reference product for the prevention of neutropenia in patients with breast cancer. The study met…
- Media Release /Study in partnership with the Alliance for Clinical Trials in Oncology is the first large controlled trial to show overall survival benefit in FLT3-mutated AML AML is the most common acute…
- Media Release /Overall response rate at 3 months was 47% (7/15) in diffuse large B-cell lymphoma and 73% (8/11) in follicular lymphoma Successful technology transfer enabling commercial scale-up of CTL019…
Pagination
- ‹ Previous page
- 1
- …
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- …
- 265
- › Next page